The first once-daily single-tablet regimen for the treatment of HIV-infected patients

被引：16

作者：

Killingley, Ben

Pozniak, Anton

机构：

[1] Northwick Pk Hosp & Clin Res Ctr, Harrow HA1 3UJ, Middx, England

[2] Chelsea & Westminster Hosp, London, England

来源：

DRUGS OF TODAY | 2007年 / 43卷 / 07期

关键词：

D O I：

10.1358/dot.2007.43.7.1086178

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Since the first description of AIDS cases over 25 years ago, great strides have been made in the treatment of HIV infection. The pursuit of new and novel therapies is ongoing, and a particular drive to simple regimens with low toxicities has been seen over the last few years. The arrival of the first once-daily single-tablet regimen is a noteworthy milestone. ATRIPLATm (Bristol-Myers Squibb, Princeton, NJ, and Gilead Sciences, Foster City, CA, USA) is a combination of three drugs that have been well studied and are currently approved as first-line agents internationally. The studies that demonstrate the efficacy and safety of these drugs are reviewed as well as the potential drawbacks. Single-tablet regimens are likely to become the therapies of choice for those commencing antiretroviral treatment, and their place in today's management is discussed. (c) 2007 Prous Science. All rights reserved.

引用

收藏

页码：427 / 442

页数：16

相关论文

共 71 条

[11] Nephrolithiasis and hydronephrosis in an HIV-infected man receiving tenofovir [J].

Cicconi, P ;

Bongiovanni, A ;

Melzi, S ;

Tordato, F ;

Monforte, AD ;

Bini, T .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2004, 24 (03) :284-285

[12] A systematic review of the associations between dose regimens and medication compliance [J].

Claxton, AJ ;

Cramer, J ;

Pierce, C .

CLINICAL THERAPEUTICS, 2001, 23 (08) :1296-1310

[13]

CLIFFORD D, 2006, 13 C RETR OPP INF DE

[14] Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals [J].

Clifford, DB ;

Evans, S ;

Yang, YJ ;

Acosta, EP ;

Goodkin, K ;

Tashima, K ;

Simpson, D ;

Dorfman, D ;

Ribaudo, H ;

Gulick, RM .

ANNALS OF INTERNAL MEDICINE, 2005, 143 (10) :714-721

[15] Periconceptional exposure to efavirenz and neural tube defects [J].

De Santis, M ;

Carducci, B ;

De Santis, L ;

Cavaliere, AF ;

Straface, G .

ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (03) :355-355

[16]

*DHHS PAN ANT GUID, GUID US ANT AG HIV 1

[17]

FORTIN C, 2004, EXPERT REV ANTI-INFE, P671

[18] Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV [J].

Gallant, JE ;

DeJesus, E ;

Arribas, JR ;

Pozniak, AL ;

Gazzard, B ;

Campo, RE ;

Lu, B ;

McColl, D ;

Chuck, S ;

Enejosa, J ;

Toole, JJ ;

Cheng, AK .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (03) :251-260

[19] Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment [J].

Gallant, JE ;

Parish, MA ;

Keruly, JC ;

Moore, RD .

CLINICAL INFECTIOUS DISEASES, 2005, 40 (08) :1194-1198

[20] Efficacy and safety of tenofovir DF vs stavuldine in combination therapy in antiretroviral-naive patients - A 3-year randomized trial [J].

Gallant, JE ;

Staszewski, S ;

Pozniak, AL ;

DeJesus, E ;

Suleiman, JMAH ;

Miller, MD ;

Coakley, DF ;

Lu, B ;

Toole, JJ ;

Cheng, AK .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (02) :191-201

← 1 2 3 4 5 6 7 8 →